rosiglitazone has been researched along with Diabetic Cardiomyopathies in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantini, G; Cosmi, L; Crescioli, C; Filardi, T; Lenzi, A; Luconi, M; Morano, S; Sottili, M | 1 |
| Breunig, IM; McPherson, ML; Shaya, FT; Snitker, S | 1 |
| Bloomgarden, Z; Handelsman, Y | 1 |
| Amin, R; Kariharan, T; Nanayakkara, G; Quindry, J; Viswaprakash, N; Zhong, J | 1 |
4 other study(ies) available for rosiglitazone and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Human cell-based anti-inflammatory effects of rosiglitazone.
Topics: Anti-Inflammatory Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Humans; Hypoglycemic Agents; Inflammation; Interferon-gamma; Interleukin-8; Myocytes, Cardiac; NF-kappa B; Prognosis; Rosiglitazone; T-Lymphocytes, Helper-Inducer; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2022 |
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fee-for-Service Plans; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Managed Care Programs; Maryland; Medicaid; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States; Young Adult | 2014 |
The Avandia debate: an unhappy conclusion.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Europe; Government Agencies; Humans; Hypoglycemic Agents; Insulin; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
PPARĪ³ activation improves the molecular and functional components of I(to) remodeling by angiotensin II.
Topics: Angiotensin II; Animals; Atrial Remodeling; Cardiotonic Agents; Cells, Cultured; Diabetic Cardiomyopathies; Down-Regulation; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocytes, Cardiac; Oxidative Stress; Potassium Channels, Voltage-Gated; PPAR gamma; Protein Transport; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling | 2013 |